C KAD
Alternative Names: C-KAD; Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution - LivionexLatest Information Update: 13 May 2024
At a glance
- Originator LIVIONEX
- Class Anticoagulants; Ethylenediamines; Eye disorder therapies; Small molecules
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cataracts
Most Recent Events
- 17 Apr 2024 Livionex has patent protection for its metal ion modulation technology (Livionex website April 2024)
- 17 Apr 2024 Efficacy data from a phase I/II trial in Cataracts released by Livionex before April 2024 (Livionex website, April 2024)
- 17 Apr 2024 Livionex plans a phase III trial for Cataracts (Opthalmic) (Livionex website, April 2024)